Rizzardi G P, Tambussi G, Barcellini W, Capiluppi B, Clerici E, Maestra L L, Lillo F, Pantaleo G, Lazzarin A
Department of Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
J Biol Regul Homeost Agents. 1997 Jan-Jun;11(1-2):43-9.
The natural course of human immunodeficiency type 1 (HIV-1) infection varies considerably. The identification of laboratory disease markers has become critically important to patient management. This study, carried out on 37 patients with primary HIV-1 infection (PHI), shows that, along with plasma HIV-1 RNA and CD4+ T cell counts, evaluation of plasma levels of some immune activation markers (sCD30, TNF-alpha, and sTNFR-I) may help to identify patients at risk of a more rapid disease progression, suggesting that immune activation is among the factors who determine the rate of disease progression. Early combination antiviral therapy significantly decreased levels of virus load and of immune activation markers, suggesting that it may reduce the extent of immune activation through the suppression of HIV-1 replication. Among others, sCD30 could be a more sensitive marker of immune activation, and it might be also useful in the monitoring of the response to antiviral therapy.
人类免疫缺陷病毒1型（HIV-1）感染的自然病程差异很大。实验室疾病标志物的识别对患者管理至关重要。这项对37例原发性HIV-1感染（PHI）患者进行的研究表明，除了血浆HIV-1 RNA和CD4+ T细胞计数外，评估一些免疫激活标志物（可溶性CD30、肿瘤坏死因子-α和可溶性肿瘤坏死因子受体-I）的血浆水平可能有助于识别疾病进展更快的风险患者，这表明免疫激活是决定疾病进展速度的因素之一。早期联合抗病毒治疗显著降低了病毒载量和免疫激活标志物水平，表明它可能通过抑制HIV-1复制来降低免疫激活程度。其中，可溶性CD30可能是免疫激活更敏感的标志物，它在监测抗病毒治疗反应方面可能也有用。
